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Abstract
Background: Chronic, low-grade inflammation provides a link between normal ageing and the pathogenesis of
age-related diseases. A series of in vitro tests confirmed the strong anti-inflammatory activities of known inhibitors
of NF-B activation (δ-tocotrienol, quercetin, riboflavin, (-) Corey lactone, amiloride, and dexamethasone). δ-
Tocotrienol also suppresses b-hydroxy-b-methylglutaryl coenzyme A (HMG-CoA) reductase activity (the rate-limiting
step in de novo cholesterol synthesis), and concomitantly lowers serum total and LDL cholesterol levels. We
evaluated these compounds in an avian model anticipating that a dietary additive combining δ-tocotrienol with
quercetin, riboflavin, (-) Corey lactone, amiloride, or dexamethasone would yield greater reductions in serum levels
of total cholesterol, LDL-cholesterol and inflammatory markers (tumor necrosis factor-a [TNF-a], and nitric oxide
[NO]), than that attained with the individual compounds.
Results: The present results showed that supplementation of control diets with all compounds tested except riboflavin,
(-) Corey lactone, and dexamethasone produced small but significant reductions in body weight gains as compared to
control. (-) Corey lactone and riboflavin did not significantly impact body weight gains. Dexamethasone significantly
and markedly reduced weight gain (>75%) compared to control. The serum levels of TNF-a and NO were decreased
61% - 84% (P < 0.001), and 14% - 67%, respectively, in chickens fed diets supplemented with δ-tocotrienol, quercetin,
riboflavin, (-) Corey lactone, amiloride, or dexamethasone as compared to controls. Significant decreases in the levels of
serum total and LDL-cholesterol were attained with δ-tocotrienol, quercetin, riboflavin and (-) Corey lactone (13% - 57%;
P < 0.05), whereas, these levels were 2-fold higher in dexamethasone treated chickens as compared to controls. Parallel
responses on hepatic lipid infiltration were confirmed by histological analyses. Treatments combining δ-tocotrienol with
the other compounds yielded values that were lower than individual values attained with either δ-tocotrienol or the
second compound. Exceptions were the significantly lower total and LDL cholesterol and triglyceride values attained
with the δ-tocotrienol/(-) Corey lactone treatment and the significantly lower triglyceride value attained with the δ-
tocotrienol/riboflavin treatment. δ-Tocotrienol attenuated the lipid-elevating impact of dexamethasone and potentiated
the triglyceride lowering impact of riboflavin. Microarray analyses of liver samples identified 62 genes whose
expressions were either up-regulated or down-regulated by all compounds suggesting common impact on serum TNF-
a and NO levels. The microarray analyses further identified 41 genes whose expression was differentially impacted by
the compounds shown to lower serum lipid levels and dexamethasone, associated with markedly elevated serum lipids.
Conclusions: This is the first report describing the anti-inflammatory effects of δ-tocotrienol, quercetin, riboflavin,
(-) Corey lactone, amiloride, and dexamethasone on serum TNF-δ and NO levels. Serum TNF-δ levels were
decreased by >60% by each of the experimental compounds. Additionally, all the treatments except with
dexamethasone, resulted in lower serum total cholesterol, LDL-cholesterol and triglyceride levels. The impact of
above mentioned compounds on the factors evaluated herein was increased when combined with δ-tocotrienol.
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Inflammatory responses to a wide variety of stimuli
are largely attributable to up-regulation of the pro-
inflammatory transcription nuclear factor kappaB
(NF-B). Specifically, reactive oxygen species (ROS) up-
regulate the pro-inflammatory NF-B transcription fac-
tor. The increased transport of NF-B to the cell
nucleus enhances expression of numerous genes encod-
ing proteins that contribute to the inflammatory pro-
cess, including inducible nitric oxide synthase (iNOS),
cyclooxygenase-2 (COX-2), tumor necrosis factors
(TNF-a,T N F - b), interleukins (IL-1, IL-6), chemokines
(IL-8, MCP1, and MIP1a), activator protein-1 (AP-1)
and adhesion factors (ICAM, and VCAM). Several of
the proteins encoded by genes that are up-regulated by
NF-B are also potent NF-B activators, thereby, form-
ing an auto-activating loop. With ageing, the capacity to
maintain a proper redox balance weakens with a conco-
mitant up-regulation of NF-B [1,2]. Age-associated
activation of NF-B has the expected effect of increasing
serum levels of TNF-a and nitric oxide (NO), and
increased NO production has been observed during
senescence [1-3]. These changes appear to be important
as there is increasing evidence to support the concept
that chronic, low-grade, and systemic inflammation con-
tributes to the development of metabolic syndrome,
dementia, cancer, atherosclerosis, osteoporosis, and
other age-related diseases [1,2].
NF-B is normally activated by degradation of inhibi-
tory kappaB (IB). When this occurs, NF-B translocates
to the nucleus and binds to specific promoter regions of
genes encoding pro-inflammatory proteins. Over the past
decade, investigators have identified a number of com-
pounds that selectively interfere with the NF-B pathway.
Several of these compounds are plant-derived antioxi-
dants [4]. Quercetin and other flavonoids [5-10], and
tocotrienols [11-18] suppress protein kinase-mediated
degradation of inhibitory kappaB (IB). This prevents
NF-B activation, and the corresponding increase in pro-
duction of various inflammatory proteins [7,9]. These
ubiquitous plant constituents have been reported to sup-
press the progression of age-related diseases [19].
Quercetin and related flavonoids improve mental
acuity [20], promote bone health [21], and attenuate
carcinogenesis [7,22,23], development of atherosclerotic
plaque [22-24], and diabetes [25]. Tocols, principally the
tocotrienols, attenuate diabetic neuropathy [16], slow
diabetes-associated cognitive decline [17], protect neu-
rons from glutamate toxicity [26], and support bone for-
mation [27]. The impact of a-, b-, g-a n dδ-tocotrienols,
the naturally-occurring farnesylated (unsaturated side-
chain) analogs of a-, b-, g-a n dδ-tocopherols, on ather-
osclerosis [28-34] and cancer [35-39] has been reported
and reviewed by several investigators (30-39). The
antioxidant activity associated with all tocols suppresses
protein kinase-mediated inhibitory kappaB (IB) degra-
dation and subsequent NF-B activation. Tocotrienols
appear to be unique among the tocols, as they suppress
hepatic HMG-CoA reductase activity and the synthesis
of mevalonate-derived products through a yet to be
defined [40] post-transcriptional mechanism [41]. As a
consequence, tocotrienols uniquely lower serum total
cholesterol and LDL-cholesterol levels [31-34,42-46].
Moreover, when evaluated in vitro, tocotrienols suppress
the synthesis of inflammatory cytokines with greater
potency than the tocopherols [11-17,47].
As delineated above, tocopherols and tocotrienols sup-
press protein kinase-mediated IB degradation and conco-
mitant NF-B activation initiated by reactive oxygen
species (ROS). The tocotrienols additionally suppress
TNF-a stimulated NF-B activation. This suppression is
reversed by treating with mevalonate and other products
of HMG-CoA reductase activity [12,14]. This reversal is
consistent with findings that Rho GTPases involved in the
regulation of NF-B require a post-translational modifica-
tion, specifically prenylation, in order to be active [48].
δ-Tocotrienol, quercetin, riboflavin, amiloride, dexa-
methasone and (-) Corey lactone (an intermediate in
prostanoid synthesis), are all FDA approved compounds
and have been used by humans for several decades with-
out any alarming adverse affects. All these compounds
inhibit lipopolysaccharide (LPS)-induced TNF-a and
iNOS gene expression in macrophages prepared from
RAW 264.7 cells, BALB/c and C57BL/6 mice [unpub-
lished results]. These key mediators of inflammation are
up-regulated during the ageing process [1-3]. Therefore,
we now evaluate the impact of the aforementioned com-
pounds on serum NO and TNF-a levels. We tested the
hypothesis that a dietary blend consisting of δ-tocotrie-
nol plus quercetin, riboflavin, (-) Corey lactone, amilor-
ide, or dexamethasone (Figure 1) would be more
effective than the individual compounds in lowering
serum NO and TNF-a levels. As described earlier, δ-
tocotrienol additionally suppresses cholesterol synthesis
and concomitantly lowers serum total cholesterol and
LDL-cholesterol levels in various experimental animal
models and humans [41-45]. We focused on the impact
of these compounds on serum levels of TNF-a,N O ,
total cholesterol, LDL-cholesterol, and triglyceride in
young female chickens. This avian model, chickens [49],
differing from the widely employed rodent model [50],
closely reflects human lipid metabolism.
Materials and methods
Materials
Sources of all chemicals, substrates, and diagnostic kits
have been identified previously [51]. Chemicals and sol-
vents were of analytical grade. Riboflavin, (-) Corey lactone
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4-hydroxymethyl-5-(4-phenylbenzoyloxy) cyclopenta
[b] furon-2-one], amiloride, and dexamethasone were pur-
chased from Sigma-Aldrich (St. Louis, MO, USA). Querce-
tin was purchased from Alfa Aesar (Johnson Matthey Co.
Lancastor, UK); lipid extracts of annatto seeds consisting
of 50% δ-tocotrienol were purchased from American River
Nutrition (Hadley, MA, USA).
Isolation of δ-tocotrienol from lipid extract of annatto seeds
Silica gel (Merck, 230-400 mesh, 60 Å, 500 g) suspended
in 1000 mL of hexane was poured into a 2-L glass funnel
with a fritted disk. The gel was washed with 2 L of
hexane prior to being loaded with 100 g of the 50%
δ-tocotrienol fraction of annatto seed in 200 mL of hex-
ane. Contaminants were washed with two liters of 10%
diethyl ether in hexane. δ-Tocotrienol was then eluted
with 30% diethyl ether in hexane (2 L). The eluted frac-
tion, evaporated under vacuum at 50°C, yielded 36 g of δ-
tocotrienol. The purity (98%) was determined by high
pressure liquid chromatography (HPLC) as described
[43].
Diets, experimental conditions
White Leghorn one-day-old female chicken and diet
ingredients were supplied by the Poultry Research
Figure 1 Chemical structures of various compounds used in this study.
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The diet consists of corn (8.8% protein, 615 g), soybean
meal (44% protein, 335 g), tocols-stripped corn oil (10
g), calcium carbonate (10 g), dicalcium phosphate (20
g), iodized salt (5 g), and mineral and vitamin mixtures
(2.5 g of each), which provided per kg feed: zinc sulfate.
H2O, 110 mg; manganese sulfate.5H2O, 70 mg; ferric
citrate.H2O, 500 mg; copper sulfate.5H2O, 16 mg;
sodium selenite, 0.2 mg; d,l-methionine, 2.5 mg; choline
chloride (50%), 1.5 g; ethoxyquin, 125 mg; thiamine.HCl,
1.8 mg; vitamin A, 1500 units; vitamin D3, 400 units;
vitamin E, 10 mg; riboflavin, 3.6 mg; calcium pantothe-
nate, 10 mg; niacin 25 mg; pyridoxine.HCl, 3 mg; fola-
cin, 0.55 mg; biotin, 0.15 mg; vitamin B12 0.01 mg; and
vitamin K, 0.55 mg. Corn additionally provided an esti-
mated 2 mg/kg tocols consisting of 12% a-tocopherol,
3% a-tocotrienol, 7% b-tocotrienol, 70% g-tocopherol,
6% g-tocotrienol, 2% δ-tocopherol, per g [52].
Day-old female chickens were fed a corn-soy meal diet
for one week before being randomly assigned to one of
24 groups. Three control groups (n = 18, housed 6/
cage/group) was fed the aforementioned commercial
diet for four weeks. One experimental group (n =6 )
was fed a diet supplemented with 50 ppm δ-tocotrienol
(125 μM/kg); twenty experimental groups were fed a
diet supplemented with 25 or 50 ppm quercetin (74, or
148 μM/kg), 25 or 50 ppm riboflavin (66.5 or 133 μM/
kg), 25 or 50 ppm (-) Corey lactone (71 or 142 μM/kg),
5o r1 0p p ma m i l o r i d e( 1 6 . 5o r3 3μM/kg), or 0.5 or 1
ppm dexamethasone (1.27 or 2.55 μM/kg) with or with-
out 50 ppm δ-tocotrienol (125 μM/kg) for four weeks.
Dietary concentrations of the aforementioned com-
pounds were derived from our preliminary studies of
their effects on TNF-a, and nitric oxide production by
RAW 264.7 cells and by macrophages prepared from
several strains of mice [unpublished results]. All treat-
ment compounds except dexamethasone were dissolved
in 50 mL 95% ethanol; dexamethasone was dissolved in
50 mL deionized water (100°C). The compounds were
mixed with the commercial diet (5 kg) in Food Mixer
for 30 min to eliminate the solvent. The experimental
diets were kept at room temperature throughout the
feeding period.
Groups were housed in a single brooder with 24 h light
and free access to water and diet. Chickens were weighed
at the start and end of the trial. At the end of 4-week
feeding period, the birds were fasted for 12 h prior to
sacrifice to facilitate chylomicron and very-low-density
lipoprotein (VLDL) clearance. The chickens were sacri-
ficed by severing their carotid arteries, rather than gas
euthanasia, in order to keep the blood (serum) composi-
tion intact for determining TNF-a and NO levels. Livers
were collected, weighed, and stored at -70°C; a small por-
tion of each liver was stored in 10% formalin and stored
at -70°C pending histological analyses. The blood samples
were incubated at 37°C for 20 min and centrifuged at
10,000 × g for 20 min to collect sera, which were held at
-70°C, pending analyses. The protocol was reviewed and
approved by the University of Wisconsin-Madison Col-
lege of Agriculture and Life Sciences Animal Care and
Use Committee. The study was carried out under a FDA
approved IND number 36906.
General biochemical methods and techniques
Assays of serum lipid parameters
The analyses of coded samples were performed at the
University of Missouri, Kansas City, School of Medicine,
MO, USA. Serum cholesterol and triglyceride levels
were estimated using Kits # 352 and 336, respectively,
purchased from Sigma Chemical Co. St. Louis, MO,
USA. LDL-cholesterol was precipitated from 200 μLo f
serum with 25 μLo fam i x t u r eo f9 . 7m Mp h o s p h o -
tungstic acid and 0.4 M MgCl2. The preparation was
mixed for 10 min at room temperature and then centri-
fuged at 12,000 × g for 20 min. The supernatant was
decanted and analyzed for HDL-cholesterol. The
remaining precipitate was dissolved in 200 μLo f0 . 1M
sodium citrate and the level of LDL-cholesterol esti-
mated as described for total cholesterol [51]. All assays
for each treatment were carried out at the same time
under similar conditions to minimize standard deviation.
Measurement of TNF-a level in serum of 5-week-old
female chickens
Levels of TNF-a in serum of chickens were determined
by Quantikine M ELISA kit (R & D System, Minneapo-
lis, MN, USA) according to manufacturer’s instructions.
The lower limit of detection for TNF-a in this method
is approximately, 5.0 pg/mL [53].
Measurement of nitric Oxide (NO) level in serum of 5-
week-old female chickens
Production of NO in serum of chickens was determined
by measuring the amount of nitrite, a stable metabolic
product of nitric oxide as described previously [54]. The
assay mixture consisted of medium (100 μL) and Griess
reagent (100 μL) placed in round-bottom 96-well tissue
culture plates (incubation time 30 min) and absorption
was measured at 570 nm on a “Microplate Reader” (MR
5000; Dynatech Labs, Inc. USA). The amount of nitrite
was determined by comparison of unknowns with a
NaNO2 standard curve. The nitrite detection limit is
0.20 nM.
Histological studies of liver samples of 5-week-old female
chickens
Liver tissues, fixed in 10% formalin, were embedded
with paraffin and cut in the sagital plane. The sections
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by light microscopy, and were evaluated by two patholo-
gists, each blinded to the treatments. A semi-quantita-
tive evaluation of histological analyses of these liver
samples was carried out according to published methods
[55]. Mean scores were assigned to each sample, scored
range 5 (presence of impact) to 40 (very severe impact).
Sample with normal appearance received a score of “0”.
The means of assigned values for each group were
determined, and based on these evaluations summary of
each treatment were reported.
Microarray data and pathway analyses of RNA of liver
samples of 5-week-old female chickens
Small frozen sections, randomly collected from each
liver within a treatment group, were pooled and the
RNA was isolated and purified using an affinity resin
column (RNeasy, Qiagen, Chatsworth, CA, USA), as
d e s c r i b e dp r e v i o u s l y[ 5 6 ]a n dt h e na n a l y z e da tM a y o
Clinic (Rochester, Minnesota, USA) using an Affymetrix
Gene-Chip (chicken), and Expression array analysis of
chicken [57]. Gene expression data were first imported
in Genespring program (Agilento Palo Alto, CA, USA).
The expression values of up-regulated genes showed
positive numbers, whereas the down-regulated genes
showed negative numbers. Various genes were identified
by using GeneSifter software. A number of sets of clus-
ter analyses of various ranges of genes sets (226, 465,
500, 1000, 1500 and 2000) were mapped to get quantita-
tive data. The analysis of amiloride was not carried out
due to published reports [58].
Statistical analysis
Stat-View software (4.01) was used for the analyses of
treatment-mediated effects (1992; Abacus Concepts, Ber-
keley, CA, USA). Treatment-mediated differences in
serum lipid (total cholesterol, LDL-cholesterol, HDL-
cholesterol, triglycerides), TNF-a and NO levels and
weight (gain, liver weight, relative liver weight) were
identified using a two-way analysis of variance
(ANOVA). When the F test indicated a significant effect,
the differences between the means were analyzed by Fish-
er’s Protected Least Significance Difference (LSD) test.
Data are reported as mean ± SD in the text and tables.
The statistical significance level was set at 5% (P < 0.05).
Results
The impact of 2-concentrations of quercetin, riboflavin,
(-) Corey lactone (25 and 50 ppm), amiloride (5 and 10
ppm) and dexamethasone (0.5 and 1 ppm) with and
without δ-tocotrienol (50 ppm) on inflammatory mar-
kers and lipid parameters were studied in 5-week-old
female chickens. On completion of the four-week study
the data revealed that varying the concentration of these
compounds failed to produce significant differences.
Consequently, we present results only for the data
reflecting results obtained by feeding the higher concen-
trations. There were 24 groups in the study, including 3
control groups. The birds of control group # 1 were
sacrificed in the beginning, # 2 in the middle (after
group # 12) and birds of third control group (# 3) were
sacrificed after group # 23. The values presented for the
control group represent the average of three control
group values (n = 18).
Effect of various compounds on weight gain and relative
liver weight gain of 5-week-old female chickens
Each of the compounds, with the exception of (-) Corey
lactone and riboflavin, significantly lowered body weight
gain (Table 1). Treatments combining δ-tocotrienol and
(-) Corey lactone or amiloride significantly increased
body weight gain when compared to the effect of the
individual compound and the control. The opposite
response, a significant lowering of body weight gain, was
detected for a treatment combining δ-tocotrienol and
dexamethasone; a similar trend, though not significant,
Table 1 Effects of various compounds on body weight
gain and relative liver weight of 5-week-old female
chickens
1
Nutritional state Body weight Liver weight/
100 g
Gain (g) Body weight
1 Control Diet (CD)
2 240.12 ± 11.37
bc 2.41 ± 0.29
ef
2C D + δ-Tocotrienol (50 ppm) 218.83 ± 8.16
e 2.42 ± 0.19
ef
3 CD + Quercetin (50 ppm) 225.50 ± 5.96
de 2.35 ±0.23
ef
4 CD + Riboflavin (50 ppm) 231.17 ± 7.52
cd 2.61 ± 0.18
cd
5 CD + (-) Corey lactone
(50 ppm)
244.00 ± 5.02
b 2.60 ± 0.18
cde
6 CD + Amiloride (10 ppm) 230.33 ± 11.91
de 2.80 ± 0.25
c
7 CD + Dexamethasone
(1.0 ppm)
57.00 ± 8.41
f 4.44 ± 0.21
b
δ-Tocotrienol (50 ppm)
blend
3
8C D + δ-T3 + Quercetin
(50 ppm)
243.50 ± 10.0
b 2.55 ± 0.23
cdef
9C D + δ-T3 + Riboflavin
(50 ppm)
228.50 ± 13.50
de 2.75 ± 0.20
cd
10 CD + δ-T3 + (-) Corey lactone
(50 ppm)
266.83 ± 13.86
a 2.48 ± 0.27
def
11 CD + δ-T3 + Amiloride
(10 ppm)
259.50 ± 4.18
a 2.27 ± 0.14
f
12 CD + δ-T3 + Dexamethasone
(1.0 ppm)
39.33 ± 7.20
g 5.75 ± 0.48
a
1Feeding period was 4 weeks; Data expressed as means ± SD = 6 chickens
per group.
2The value of control group was an average of 3 control groups.
3The diets of groups 8 - 12 were supplemented with δ-tocotrienol (50 ppm).
a-gValues in columns not sharing a common superscript letter are significantly
different at P < 0.05.
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and riboflavin. Treatment-mediated impacts on feed effi-
ciency (grams feed/gram weight gain) and liver weight
paralleled those noted for weight gain (Table 1). Ribofla-
vin, amiloride, and to a much greater extent, dexa-
methasone, significantly increased relative liver weights
when compared to that of the control group. δ-Toco-
trienol attenuated the impact of amiloride on relative
liver weight as shown in Table 1.
The impacts of the treatments on liver slices (histolo-
gical analyses) are recorded in Table 2. Severe chronic
inflammation with mild fatty infiltration was recorded
for the liver samples of control group. All individual
treatments reduced the extent of inflammation (Table 2;
Figure 2). Combining δ-tocotrienol with quercetin, ribo-
flavin, (-) Corey lactone, or amiloride, yielded greater
reductions in inflammation and fatty infiltration than
the reductions achieved with individual compounds.
Combining δ-tocotrienol with dexamethasone yielded a
significant increase in relative liver weight compared to
that of the dexamethasone group (Table 1), and livers
were severely compromised as shown by histological
analyses (Figure 2).
Effects of various compounds on serum levels of TNF-a
and NO of 5-week-old female chickens
T h ed a t as h o w ni nF i g u r e s3 ,4 ,5 ,6 ,7 ,8a r ep r e s e n t e d
in two different formats. For each Figure., ‘A’ shows the
raw values for each of the treatments and control, and
‘B’ shows the percent change compared to control.
Each of the experimental compounds significantly low-
ered serum TNF-a levels (Figure 3A, B). The decreases
in serum levels of TNF-a with δ-tocotrienol (83%), quer-
cetin (84%), riboflavin (81%), (-) Corey lactone (83%),
amiloride (72%), and dexamethasone (61%), were
significant (P < 0.01) as compared to control. Treatments
combining δ-tocotrienol with the remaining compounds
produced further reductions in serum levels of TNF-a
with quercetin (5%), riboflavin (11%), (-) Corey lactone
(5), amiloride (16%), and dexamethasone (13%) that were
considered non-significant due to large standard devia-
tion (>18% - 45%) in all groups (Figure 3B).
Serum NO levels were significantly lowered by treat-
ments comprising only of δ-tocotrienol (45%), (-) Corey
lactone (31%), and dexamethasone (67%) (P < 0.002) com-
pared to control (Figure 4A, B). However, in comparing
the results of combined supplementation vs. single com-
pound supplementation, the addition of δ-tocotrienol to
all compounds tested produced further significant (P <
0.001) reductions in serum NO levels with quercetin
(25%), riboflavin (34%), (-) Corey lactone (18%), amiloride
(32%), and dexamethasone (11%), as compared to their
respective individual reduction (Figure 4B). It is important
to note that the reduction of serum NO with δ-tocotrienol
(45%) alone closely resembles the values of combined
treatments of δ-tocotrienol with quercetin, riboflavin, (-)
Corey lactone, amiloride (approximately 50%), except dex-
amethasone, which showed maximum reduction of serum
NO (67%) alone versus combined treatment with δ-toco-
trienol (78%; Figure 4B). These pronounced reductions of
TNF-a and NO by δ-tocotrienol with a dose of 50 ppm
may be due to maximal attenuation achieved with this
dose, indicating that it is a very potent anti-inflammatory
agent. The lower dose of δ-tocotrienol (10 or 20 ppm) in
combination with quercetin, riboflavin or (-) Corey lactone
may produce far better additive effects than observed in
the present study. In summary, the pronounced reductions
of serum TNF-a and NO levels by a near saturating con-
centration of δ-tocotrienol, likely, masked the responses to
be gained with combined treatments.
Table 2 Effects of δ-tocotrienol and various compounds on histological analyses of liver samples of 5-week-old female
chickens
1
# Nutritional state Histological analyses of chicken liver samples
1 Control Diet (CD) Severe chronic inflammation & mild fatty infiltration
2C D + δ-Tocotrienol (50 ppm)
2 Mild chronic inflammation
3 CD + Quercetin (50 ppm) Moderate chronic inflammation & mild fatty infiltration
4 CD + Riboflavin (50 ppm) Moderate chronic inflammation & mild fatty infiltration
5 CD + (-) Corey lactone (50 ppm) Mild chronic inflammation & moderate fatty infiltration
6 CD + Amiloride (10 ppm) Mild chronic inflammation & moderate fatty infiltration
7 CD + Dexamethasone (1.0 ppm) Mild chronic inflammation & moderate fatty infiltration
δ-Tocotrienol (50 ppm) blend
2
8C D + δ-T3 + Quercetin (50 ppm) Moderate chronic inflammation & mild fatty infiltration
9C D + δ-T3 + Riboflavin (50 ppm) Very mild chronic inflammation
10 CD + δ-T3 + (-) Corey lactone (50 ppm) Very mild chronic inflammation & autolysis
11 CD + δ-T3 + Amiloride (10 ppm) Very mild chronic inflammation
12 CD + δ-T3 + Dexamethasone (1.0 ppm) Autolysis
1Feeding period was 4 wk; Data expressed as means ± SD = 6 chickens per group.
2The diets of groups 8 - 12 were supplemented with δ-tocotrienol (50 ppm).
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parameters of 5-week-old female chickens
Serum total and LDL-cholesterol levels in chickens fed
the δ-tocotrienol-supplemented diet were 77%, and 55%
of control level, respectively (Figures 5, 6). These obser-
vations are consistent with results from numerous
clinical trials [18,31-34,51]. All of the remaining com-
pounds, with the exception of dexamethasone, signifi-
cantly lowered serum total cholesterol levels, (-) Corey
lactone by 31%, riboflavin by 22%, quercetin by 13%
and amiloride by 9% (P < 0.05) compared to control
(Figures 5, 6). Dexamethasone significantly increased
Figure 2 Effects of dietary supplements on histological analyses of livers of 5-week-old female chickens. The scans 1-12 shows the
histological evaluation of representative liver sections from chickens treated with or without δ-tocotrienol with other compounds: 1. control diet;
2. δ-tocotrienol (δ-T3); 3. quercetin; 4. riboflavin; 5. (-) Corey lactone; 6. amiloride; 7. dexamethasone; 8. δ-T3 + quercetin; 9. δ-T3 + riboflavin; 10.
δ-T3 + (-) Corey lactone; 11. δ-T3 + amiloride; 12. δ-T3 + dexamethasone.
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groups were described in detail in the Methods section. Chickens were fed for 4 weeks. The diets of groups 8 - 12 were supplemented with δ-
tocotrienol (50 ppm). Data expressed as means ± SD, n = 6 chickens per group. The value for the control group was the average of 3 control
groups. Values in columns not sharing a common symbol were significantly different at P < 0.05. For each figure, ‘A’ shows the raw values for
each of the treatments and control, and ‘B’ shows the percent change compared to control. The groups 1-12 correspond to: 1. control diet; 2; δ-
tocotrienol (δ-T3); 3. quercetin; 4. riboflavin; 5. (-) Corey lactone; 6. amiloride; 7. dexamethasone; 8. δ-T3 + quercetin; 9. δ-T3 + riboflavin; 10. δ-T3
+ (-) Corey lactone; 11. δ-T3 + amiloride; 12. δ-T3 + dexamethasone.
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Page 8 of 22Figure 4 Effects of dietary supplements on the serum levels of nitric oxide (NO) of 5-week-old female chickens. Chickens were fed for 4
weeks. The diets of groups 8 - 12 were supplemented with δ-tocotrienol (50 ppm). Data expressed as means ± SD, n = 6 chickens per group.
The value for the control group was the average of 3 control groups. Values in columns not sharing a common symbol were significantly
different at P < 0.05. For each figure, ‘A’ shows the raw values for each of the treatments and control, and ‘B’ shows the percent change
compared to control. The groups 1 - 12 correspond to: 1. control diet; 2; δ-tocotrienol (δ-T3); 3. quercetin; 4. riboflavin; 5. (-) Corey lactone; 6.
amiloride; 7. dexamethasone; 8. δ-T3 + quercetin; 9. δ-T3 + riboflavin; 10. δ-T3 + (-) Corey lactone; 11. δ-T3 + amiloride; 12. δ-T3 +
dexamethasone.
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Page 9 of 22Figure 5 Effects of dietary supplements on the serum levels of total cholesterol of 5-week-old female chickens. Chickens were fed for 4
weeks. The diets of groups 8 - 12 were supplemented with δ-tocotrienol (50 ppm). Data expressed as means ± SD, n = 6 chickens per group.
The results were reported in SI units (mmo/L). The value for the control group was the average of 3 control groups. Values in columns not
sharing a common symbol were significantly different at P < 0.05. For each figure, ‘A’ shows the raw values for each of the treatments and
control, and ‘B’ shows the percent change compared to control. The groups 1 - 12 correspond to: 1. control diet; 2; δ-tocotrienol (δ-T3); 3.
quercetin; 4. riboflavin; 5. (-) Corey lactone; 6. amiloride; 7. dexamethasone; 8. δ-T3 + quercetin; 9. δ-T3 + riboflavin; 10. δ-T3 + (-) Corey lactone;
11. δ-T3 + amiloride; 12. δ-T3 + dexamethasone.
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Figure 6 Effects of dietary supplements on the serum levels of LDL-cholesterol of 5-week-old female chickens. Chickens were fed for 4
weeks. The diets of groups 8 - 12 were supplemented with δ-tocotrienol (50 ppm). Data expressed as means ± SD, n = 6 chickens per group.
The results were reported in SI units (mmo/L). The value for the control group was the average of 3 control groups. Values in columns not
sharing a common symbol were significantly different at P < 0.05. For each figure, ‘A’ shows the raw values for each of the treatments and
control, and ‘B’ shows the percent change compared to control. The groups 1 - 12 correspond to: 1. control diet; 2; δ-tocotrienol (δ-T3); 3.
quercetin; 4. riboflavin; 5. (-) Corey lactone; 6. amiloride; 7. dexamethasone; 8. δ-T3 + quercetin; 9. δ-T3 + riboflavin; 10. δ-T3 + (-) Corey lactone;
11. δ-T3 + amiloride; 12. δ-T3 + dexamethasone.
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Figure 7 Effects of dietary supplements on the serum levels of HDL-cholesterol of 5-week-old female chickens. Chickens were fed for 4
weeks. The diets of groups 8 - 12 were supplemented with δ-tocotrienol (50 ppm). Data expressed as means ± SD, n = 6 chickens per group.
The results were reported in SI units (mmo/L). The value for the control group was the average of 3 control groups. Values in columns not
sharing a common symbol were significantly different at P < 0.05. For each figure, ‘A’ shows the raw values for each of the treatments and
control, and ‘B’ shows the percent change compared to control. The groups 1 - 12 correspond to: 1. control diet; 2; δ-tocotrienol (δ-T3); 3.
quercetin; 4. riboflavin; 5. (-) Corey lactone; 6. amiloride; 7. dexamethasone; 8. δ-T3 + quercetin; 9. δ-T3 + riboflavin; 10. δ-T3 + (-) Corey lactone;
11. δ-T3 + amiloride; 12. δ-T3 + dexamethasone.
Qureshi et al. Lipids in Health and Disease 2011, 10:39
http://www.lipidworld.com/content/10/1/39
Page 12 of 22Figure 8 Effects of dietary supplements on the serum levels of triglyceride of 5-week-old female chickens. Chickens were fed for 4
weeks. The diets of groups 8 - 12 were supplemented with δ-tocotrienol (50 ppm). Data expressed as means ± SD, n = 6 chickens per group.
The results were reported in SI units (mmo/L). The value for the control group was the average of 3 control groups. Values in columns not
sharing a common symbol were significantly different at P < 0.05. For each figure, ‘A’ shows the raw values for each of the treatments and
control, and ‘B’ shows the percent change compared to control. The groups 1 - 12 correspond to: 1. control diet; 2; δ-tocotrienol (δ-T3); 3.
quercetin; 4. riboflavin; 5. (-) Corey lactone; 6. amiloride; 7. dexamethasone; 8. δ-T3 + quercetin; 9. δ-T3 + riboflavin; 10. δ-T3 + (-) Corey lactone;
11. δ-T3 + amiloride; 12. δ-T3 + dexamethasone.
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Page 13 of 22serum level of total cholesterol to 220% (P < 0.001) of
control level (Figure 5), an impact that was attenuated,
by the addition of δ-tocotrienol. Although the combined
treatments produced modest reductions (6% to 12%) in
serum total cholesterol level when compared to reduc-
tions achieved with the individual compounds (Figure
5B), only the combination of δ-tocotrienol and (-)
Corey lactone produced a greater reduction in serum
total cholesterol levels than that achieved with δ-toco-
trienol (Figure 5B).
Treatment-mediated effects on serum LDL-cholesterol
levels were generally comparable to the effects of total
cholesterol. With the exception of dexamethasone, all of
the individual treatments yielded significantly lowered
serum LDL-cholesterol levels (21% - 51%; P < 0.001) as
compared to control (Figure 6). Dexamethasone signifi-
cantly increased serum LDL-cholesterol level to 230% of
control level (Figure 6B). The effect of dexamethasone
was significantly attenuated by the addition of δ-toco-
trienol (Figure 6B). Although combined treatments com-
prised of δ-tocotrienol and quercetin, riboflavin, (-)
Corey lactone and amiloride yielded serum LDL-choles-
terol levels lower than those attained with the individual
agents, only the combination of δ-tocotrienol and (-)
Corey lactone yielded a level significantly lower than
that attained with δ-tocotrienol (Figure 6B).
Consistent with other reports [18,31-34,51], supple-
mentation with δ-tocotrienol had no impact on HDL-
cholesterol level (Figure 7). Quercetin, riboflavin and (-)
Corey lactone lowered serum HDL-cholesterol levels
modestly. Dexamethasone significantly increased serum
HDL-cholesterol level to 218% of control (Figure 7B).
The increase observed with dexamethasone alone was
also attenuated by the addition of δ-tocotrienol, compar-
able to the findings with serum total cholesterol and
LDL-cholesterol levels. Serum HDL-cholesterol levels in
chickens treated with dexamethasone plus δ-tocotrienol
were 182% of control level (Figure 7B). In comparing
the results of combined dietary supplementation with
single compound, the addition of δ-tocotrienol to all
compounds tested, except amiloride, did not produce
further reductions in serum HDL-cholesterol levels
(Figure 7B). Individually, neither δ-tocotrienol nor amilor-
ide reduced serum HDL-cholesterol levels; the combina-
tion of δ-tocotrienol plus amiloride, however, modestly
reduced serum HDL-cholesterol level (Figure 7B).
With the exception of dexamethasone, all of the indi-
vidual treatments yielded significantly lowered serum
triglyceride levels (9% - 24%; P < 0.002) of control
group (Figure 8). Dexamethasone significantly increased
the serum triglyceride level by 17% (P < 0.001) of con-
trol (Figure 8B). This increase observed with dexametha-
sone was completely abrogated by the addition of
δ-tocotrienol; serum triglyceride level in chickens treated
with dexamethasone plus δ-tocotrienol was 103% of
control level (Figure 8B). In comparing the results of
combined treatments with single compound treatments,
the addition of δ-tocotrienol to all compounds tested
produced additional reductions in serum triglyceride
l e v e l s( F i g u r e8 B ) ,o n l yt h a ta c h i e v e db yc o m b i n i n gδ-
tocotrienol with amiloride was significant.
To summarize the results presented above, serum
total cholesterol, LDL cholesterol, and triglyceride levels
were generally decreased by diets supplemented with δ-
tocotrienol, quercetin, riboflavin, or (-) Corey lactone,
and minimally with amiloride. Treatments combining δ-
tocotrienol with quercetin, riboflavin, (-) Corey lactone,
or amiloride generally produced additional but mostly
non-significant reductions. Dexamethasone increased
serum total cholesterol, LDL-cholesterol, HDL-choles-
terol, and triglyceride levels (Figures 5B, 8B). These
increases in serum total and LDL-cholesterol levels with
dexamethasone were attenuated by the addition of δ-
tocotrienol.
Microarray analyses of RNA of liver samples of 5-week-
old female chickens
Cluster microarray data analyses of mRNA from pooled
liver samples of each treatment using GeneSifter pro-
gram provided valuable information comprising of 465
genes. Out of 465 genes, there were at least 62 genes
whose expression was either up-regulated or down-
regulated by δ-tocotrienol, quercetin, riboflavin, (-)
Corey lactone, and dexamethasone. These 62 genes
were categorized under inflammation, ageing, cardiovas-
cular disease and cancer (Tables 3, 4). Out of 62 genes,
only 39 genes were up-regulated (Table 3) and 23
down-regulated (Table 4) by these compounds. The
expression of genes up-regulated by these compounds
were associated with inflammation (9 genes), ageing (7
genes), cardiovascular disease (20 genes), and cancer (3
genes) as shown in Table 3. These compounds modu-
lated the expression of a number of genes, such as:
interferon 1 receptor, cytokine signaling, NFB and ubi-
quitin protein lipase (inflammation), heat shock protein,
RIKEN cDNA, ATPase, T cell receptor gamma (ageing),
FAS, myosin, squalene epoxidase, NADH dehydrogen-
ase, Prostaglandin D2 synthase, coagulation factor II
(cardiovascular), and RAN, member of RAS oncogene
family (cancer) as shown in Table 3.
The expression of genes down-regulated by these
compounds were associated with inflammation
(9 genes), ageing (7 genes), cardiovascular disease
(6 genes), and cancer (7 genes) (Table 4). Some of the
important genes whose expression was modulated by
these compounds included those of proteasome, protein
kinase, tumor necrosis factor (inflammation), carnitine
palmitoyltransferase 1A, nuclear DNA-binding protein
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Page 14 of 22(ageing), glycogen synthase kinase, glutathione S-trans-
ferase (cardiovascular), RAS guanyl releasing protein 3,
and Jun oncogene (cancer) (Table 4). The Jun oncogene
also plays important role in ageing.
The detailed analyses of genes whose expressions modu-
lated by δ-tocotrienol, quercetin, riboflavin, (-) Corey
lactone and dexamethasone, regulated differentially, were
also selected (Tables 5, 6). Among these compounds, the
first four were associated with lowering of serum lipids
and latter, dexamethasone, associated as a lipid-elevating
compound. Expression of 20 genes was up-regulated and
7 genes down-regulated by δ-tocotrienol, quercetin,
Table 3 Microarray analyses of RNA of livers of chicken after treatment with various compounds
Genes Up-regulated
# Genes Control δ-T3 Quer Ribo Co lac Dexa Description
Inflammation
1 BX932265 0.15 1.30 3.69 1.57 2.78 1.83 Endothelin receptor type 2
2 BU449947 0.81 1.92 3.54 2.05 2.81 1.73 Endothelin receptor type B
3 AJ719289 1.10 2.65 3.12 2.10 2.75 2.07 Ubiquitin protein lipase E3C
4 NM_204124 1.12 2.40 3.12 3.09 3.11 2.03 Nuclear receptor subfamily 2, group C, member 1
5 AF082666 1.22 1.89 3.24 1.92 1.86 1.01 Interleukin 10 receptor, beta
6 CF256615 1.96 4.37 4.40 3.60 4.55 3.26 Interferon-gamma receptor alpha chain precursor
7 BU313956 2.41 2.75 4.64 2.99 3.24 3.21 Suppressor of cytokine signaling 1
8 AJ720966 2.54 4.72 4.95 4.29 4.66 4.09 Nuclear factor kappaB related to binding protein
9 NM_205485 3.35 4.40 5.91 5.06 5.28 5.10 Interferon 1 receptor, type 1
Ageing
10 CR523238 0.50 1.46 2.55 0.44 2.21 0.92 Palmitoyl-protein thioesterase 1
11 U22666 0.75 4.62 4.48 4.50 3.00 2.66 T cell receptor gamma
12 BX950427 0.97 3.37 4.68 2.44 4.25 2.29 RIKEN cDNA C230081A13
13 AF175433 1.96 4.00 5.05 3.80 3.50 2.20 T cell receptor delta chain (TCRD)
14 NM_205520 3.23 4.04 5.55 3.66 4.15 3.32 ATPase, Na+/K+ transporting, beta 1 polypeptide
15 AF387865 4.67 6.17 7.02 5.55 6.49 6.44 Heat shock protein 90 Da beta (Grp94), member 1
16 BX932093 6.04 8.07 8.34 7.24 8.47 8.01 PIT 54 protein
Cardiovascular
17 CR524241 0.46 3.47 6.00 2.39 6.61 6.57 Succinate-CoA ligase, GDP-forming, beta subunit
18 ENSGAL T4 0.48 1.73 2.55 1.81 1.91 1.06 Glycerol kinase 5
19 CR325238 0.50 1.46 2.55 0.44 2.21 0.92 Palmitoyl-protein thioesterase 1
20 ENSGAL T26 0.55 2.92 3.79 2.96 2.92 1.90 Cytosolic methionine-S-sulfoxide reductase
21 NM_205274 0.71 2.15 3.51 2.00 3.49 2.39 Myosin, heavy chain 11, smooth muscle
22 J04598 0.85 2.79 3.69 1.89 3.15 1.32 Collagen, type VI, alpha 1
23 ENSGAL T6 1.45 3.57 4.09 2.79 3.88 2.40 Plasminogen precursor
24 ENSGAL T5 1.53 2.99 4.09 3.17 3.78 3.29 Aldehyde dehydrogenase 9 family, member A1
25 BU235638 1.54 3.51 5.21 4.32 4.21 2.15 Serine hydroxymethyltransferase 1 (soluble)
26 BX930122 1.75 3.12 3.64 3.11 3.90 2.61 Aldehyde dehdrogenase 8 family member A1
27 ENSGAL T12 2.25 4.26 4.82 3.59 5.05 3.61 Glucose 6-phosphate translocase
28 AJ720577 2.37 4.78 6.86 4.80 6.74 5.97 NADH dehydrogenase (Ubiquinone) Fe-S protein 1
29 NM_204259 2.48 5.88 6.02 5.75 5.70 3.67 Prostaglandin D2 synthase 21 KDa
30 AJ720030 3.29 5.00 5.62 5.35 5.13 1.62 Squalene epoxidase
31 NM_205483 3.50 5.60 5.60 4.48 3.97 3.72 Lipoprotein
32 ENSGAL T10 3.83 5.08 5.43 5.49 5.89 3.28 Enoyl-coenzyme A, hydratase/3-hydroxyacyl coenz
33 NM_2051155 4.73 5.52 6.87 5.48 5.79 6.09 Fatty acid synthase
34 ENSGAL T20 5.09 5.86 7.01 6.32 7.11 5.70 Alcohol dehydrogenase 1C (class 1), g-polypeptide
35 NM_204605 5.83 7.57 7.98 7.05 7.68 6.68 Coagulation factor II (thrombin)
36 BX931521 6.36 8.27 8.94 8.12 8.43 8.63 Glutathione peroxide 3 precursor (GSHPx-3)
Cancer
37 AJ720735 0.18 1.76 2.70 0.90 2.87 1.37 Endoplasmic reticulum protein 29
38 BU117693 1.51 2.98 3.56 2.68 2.93 2.48 RAN, member RAS oncogene family
39 ENSGAL T6 2.60 5.10 5.88 4.53 5.81 4.98 Similar to cytochrome P450, family 2, subfamily W,
δ-T3 = δ-Tocotrienol; Quer. = Quercetin; Ribo = Riboflavin; (-) Co lac = (-) Corey lactone; Dexa = Dexamethasone.
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Page 15 of 22riboflavin, (-) Corey lactone, except for a lipid elevating,
dexamethasone (Table 5). Expression of 8 genes was up-
regulated by first four compounds and down-regulated by
dexamethasone, and 2 genes were down-regulated by first
four compounds and up-regulated by dexamethasone
(Table 6). Moreover, expression of 2 genes was up-regu-
lated by dexamethasone, and not by the four lipid-lower-
ing compounds and 1 gene was down-regulated by
dexamethasone, and no effect was observed with the four
lipid-lowering (δ-tocotrienol, quercetin, riboflavin, (-)
Corey lactone) compounds (Table 6).
Discussion
On average, the weight of chickens fed the control diet
increased by 240 g during the four-week trial. In the cur-
rent study, we found chickens fed a diet supplemented
with δ-tocotrienol gained significantly less weight. This
finding differs from results of earlier trials demonstrating
that diet supplementation with δ-tocotrienol produced
either no change, or an increase in weight gain [43,51].
Quercetin, amiloride, and dexamethasone yielded
significantly lower weight gain, whereas riboflavin and (-)
Corey lactone had no significant effect on weight gain.
Interestingly, combined supplementation consisting of δ-
tocotrienol plus either (-) Corey lactone or amiloride sig-
nificantly increased weight gain; the combination of
δ-tocotrienol and quercetin produced a weight gain equal
to that of the control. Thus for (-) Corey lactone, amilor-
ide, and quercetin, additional supplementation with
δ-tocotrienol appeared to increase weight gains, as com-
pared to dietary supplementation with each of these
compounds alone. The addition of δ-tocotrienol to ribo-
flavin did not improve weight gains compared to dietary
supplementation with riboflavin alone. As reported else-
where, dietary supplementation with dexamethasone
markedly reduced weight gain compared to control
[59,60], and this detrimental effect was enhanced by
combining dexamethasone with δ-tocotrienol.
Histological examination demonstrated decreased
inflammation in livers from chickens receiving individual
treatments. Treatments combining δ-tocotrienol with
either riboflavin, (-) Corey lactone, or amiloride yielded
Table 4 Microarray analyses of RNA of livers of chickens after treatment with various compounds
Genes down-regulated
# Genes Control δ-T3 Quer Ribo Co lac Dexa Description
Inflammation
1 AJ719859 3.33 2.03 2.42 1.74 1.93 1.18 Proteasome (prosome, macropain) activator subunit 4
2 BX950555 4.01 4.11 4.38 3.78 3.38 1.64 Tumor necrosis factor superfamily, # 5-induced protein
3 BU397996 4.53 2.82 2.18 2.74 2.20 2.87 Protein Kinase
Ageing
4 CR353144 4.03 1.66 3.57 3.12 2.92 3.18 Nuclear DNA-binding protein
5 BU426315 4.50 2.20 2.42 2.14 1.70 1.33 Carnitine palmitoyltransferase 1A (liver)
6 CR523285 4.60 2.35 3.26 1.90 3.68 8.02 Finshed cDNA clone ChEST613j16
7 CD735693 6.05 4.25 5.44 4.66 3.68 3.39 Heat shock protein 25
8 BU123548 6.47 6.16 7.31 6.30 6.14 4.20 Finshed cDNA clone ChEST495e19
9 NM_205471 8.73 6.99 8.76 7.69 7.42 6.28 Phosphoenolpyruvate carboxykinase 1
10 CR523582 6.79 5.31 4.78 5.19 4.66 4.84 B-cell CLL/lymphoma 9
Cardiovascular
11 M64990 3.94 1.69 1.51 2.10 1.02 1.25 Prostaglandin-endoperoxide synthase 2
12 CR522967 4.42 3.41 2.18 3.20 2.53 3.67 KIAA1285 protein
13 ENSGAL T24 5.31 3.93 5.00 4.42 4.60 3.05 Aproteindipose differentiation-related
14 BX935098 5.79 4.45 5.41 4.35 4.52 3.09 Glutathione S-transferase theta 1
15 BU422942 5.84 4.14 3.65 4.09 3.79 4.41 Glycogen synthase kinase 3 beta
16 BU272340 6.58 5.63 4.23 5.47 5.39 5.81 Inositol hexaphosphate kinase 2
Cancer
17 AJ447153 2.19 0.83 2.06 1.56 1.21 0.01 Protein tyrosine phosphate, non-receptor type 2
18 BU463093 3.63 2.67 4.07 2.78 3.28 0.90 Amino acid transporter system A1
19 AL585963 3.95 2.15 1.74 1.20 2.07 1.67 RAS guanyl releasing protein 3
20 ENSGAL T0 4.24 3.18 1.62 2.42 1.85 2.97 Breast cancer-associated antigen BRCAA 1
21 BU131710 4.47 4.36 5.24 5.28 4.35 2.31 Isopentenyl-diphosphate delta isomerase 1
22 BU111042 6.54 5.46 4.39 4.81 4.98 5.95 Chrosome 6 open reading frame 111; SR rich protein
23 BU458470 7.84 5.78 7.08 6.96 5.90 5.90 Jun oncogene
δ-T3 = δ-Tocotrienol; Quer. = Quercetin; Ribo = Riboflavin; Co lac = (-) Corey lactone; Dexa = Dexamethasone.
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Page 16 of 22further decreases in hepatic inflammation and fatty infil-
tration. On the other hand δ-tocotrienol potentiated the
toxic impact of dexamethasone. Dexamethasone toxicity,
previously demonstrated in rats, was manifested by
impaired growth, enlarged livers, and elevated serum
total cholesterol and triglyceride levels [59-61].
All predictors of cardiovascular risk evaluated in this
study were substantially decreased by all compounds
with the exception of dexamethasone. Summarizing the
overall effects of the individual compound on the five
serum factors under consideration (TNF-a, NO, total
cholesterol, LDL-cholesterol, and triglyceride) leads to
the conclusion that the cumulative risk of atherosclero-
sis is reduced effectively by δ-tocotrienol, quercetin,
riboflavin, and (-) Corey lactone.
Serum TNF-a levels of chickens receiving each of the
compounds were uniformly lower than those recorded
for chickens fed the control diet. Serum levels of TNF-a
of chickens treated with δ-tocotrienol, quercetin, ribofla-
vin, and (-) Corey lactone were reduced by approxi-
mately 80%. Serum TNF-a levels of chickens treated
with dexamethasone and amiloride were reduced by
approximately 41% and 70%, respectively. These findings
are consistent with prior reports of the effects riboflavin
[62-64], quercetin [5,9,10,65], δ-tocotrienol [15-17],
amiloride [66] and dexamethasone [67] in vitro
[9,10,15-17,21] and in vivo [62-64] on TNF-a level.
δ-Tocotrienol produced a 45% reduction in the serum
NO level. Quercetin, riboflavin, (-) Corey lactone,
amiloride, and dexamethasone reduced serum NO levels
by 14%, 14%, 31%, 25%, and 67%, respectively. Quercetin
has been reported to down-regulate inducible-NO
synthase (iNOS) activity in vitro [5-10,68], and ribofla-
vin, delivered by injection or infusion, inhibits NO
synthesis and the concomitant increases in serum NO
level in LPS-challenged mice [62-64]. Perhaps the most
Table 5 Microarray analyses of RNA of livers of chickens after treatment with various compounds
Genes up-regulated by the first four lipid-lowering compounds and lipid-raising dexamethasone
# Genes Control δ-T3 Quer Ribo Co lac Dexa Description
1 BX275358 3.42 6.22 6.09 6.66 5.39 3.31 Putative ISG 12-2 protein
2 BU235638 1.54 3.51 5.21 4.32 4.21 2.15 Similar to serine hydroxymethyltransferase 1 (soluble)
3 ENSGL T6 3.98 6.05 6.93 5.53 7.15 4.59 UDP glucuronosyltransferase 1 family, polypeptide A10
4 CF256116 1.85 3.58 4.64 3.76 4.57 1.91 Phosphoribosyl pyrophosphate amidotransferase
5 NM_204858 -0.48 0.95 2.05 1.49 1.70 -0.13 Interferon (alpha, beta, and omega) receptor 2
6 AY534896 6.19 8.22 8.56 8.00 7.91 6.40 Gal 10
7 JO4598 0.85 2.79 3.69 1.89 3.15 1.32 Collagen, type IV, alpha 1
8 ENSGALT2 6.32 8.29 8.95 7.64 8.48 6.78 Similar to inter-alpha (globulin) inhibitor H3
9 ENSGALT27 0.84 3.10 3.18 2.23 2.50 0.87 Similar to KDEL (Lys-Asp-Glu-Leu) containing 1
10 M60069 6.14 8.06 6.71 7.57 7.88 6.00 Phosphoribosyl pyrophosphate amidotransferase
11 ENSGALT15 4.35 5.38 7.00 5.96 6.71 4.52 Similar to MGC 107895 protein
12 BX275222 0.23 2.43 2.64 1.24 1.59 0.19 Hypothetical protein LOC69044
13 ENSGALT27 4.80 6.48 7.13 5.83 6.84 5.06 Similar to thrombin-activatable fibrinosis inhibitor
14 BU219227 1.60 2.82 4.09 3.16 3.21 1.92 WD repeat domain 61
15 NM_205299 2.29 3.38 4.62 3.39 3.66 2.33 Dystrophin
16 ENSGALT26 2.10 3.46 4.27 3.23 3.67 2.66 Similar to methylmalonyl coenzyme A mutase
17 NM_205355 4.83 6.24 7.15 5.98 6.12 5.21 Ring finger protein 13
18 ENSGALT3 3.62 4.91 5.89 4.33 6.40 3.78 Similar to complement regulator factor H
19 CR290617 3.27 4.77 5.74 4.17 4.96 3.41 RER1 retention in endoplasmic reticulum 1 homolog
20 ENSGALT4 0.99 2.51 3.36 1.79 2.62 1.12 Similar to U1 snRNP-specific protein C
21 AF082666 1.22 1.89 3.24 1.92 1.86 1.01 Interleukin 10 receptor, beta
Genes down-regulated by the first four lipid-lowering compounds except dexamethasone
# Genes Control δ-T3 Quer Ribo Co lac Dexa Description
1 ENSGALT20 2.01 1.14 -0.34 1.29 0.73 2.35 Similar to Trans-Golgi p230
2 BU270035 2.54 1.06 1.03 -0.08 1.25 2.59 Similar to Expressed soquence A1314180
3 BU208119 3.84 3.14 1.33 2.13 1.93 3.51 Similar to RIKEN cDNA D130059P03 gene
4 BU229724 5.44 3.99 2.96 3.49 3.57 5.55 Finshed cDNA, clone Chest295h22
5 ENSGALT9 1.84 -0.43 -0.23 0.75 -0.57 2.50 Similar to KIAA07 protein
6 BU305188 6.08 4.75 3.02 4.19 3.99 5.71 PCF11, cleavage and polyadenylation factor subunit
7 BU426927 3.76 2.44 -0.14 1.83 0.97 3.63 Triple functional domain (PTPRF interacting)
δ-T3 = δ-Tocotrienol; Quer. = Quercetin; Ribo = Riboflavin; Co lac = (-) Corey lactone; Dexa = Dexamethasone.
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Page 17 of 22important result of the present study is the finding that
combining δ-tocotrienol with other dietary supplements
enhances suppression of serum NO and TNF-a levels,
as compared to single compound supplementation;
these results are particularly striking for NO level.
Although, reduction of serum NO level with δ-tocotrie-
nol alone closely resembles the reductions of δ-tocotrie-
nol combined with other compounds, which may be due
to maximal attenuations achieved with a dose of δ-toco-
trienol (50 ppm) used in the present study. In our ear-
lier dose-response study of δ-tocotrienol effects on the
serum levels of total cholesterol and LDL-cholesterol in
chickens, the maximum effective dose was found to be
200 ppm (51). Therefore, a minimum effective dose of
50 ppm was selected for the present study. This is the
first report that describes the effects of δ-tocotrienol for
avian pro-inflammatory markers (TNF-a and NO),
which is consistent with findings that δ-tocotrienol is
very potent anti-inflammatory compound as reported
recently (47), and it is possible a lower dosage (10 or 20
ppm) of δ-tocotrienol may potentiate the anti-inflamma-
tory actions of quercetin, riboflavin and (-) Corey
lactone.
All treatments, except those involving dexamethasone,
resulted in significantly lower serum total cholesterol,
LDL-cholesterol and triglyceride levels. The effects of δ-
tocotrienol and (-) Corey lactone on serum levels of total
and LDL-cholesterol were significantly greater than those
of the other compounds (Figures 5, 6, 8). Our current
study appears to be the first observation of the choles-
terol-lowering impact of (-) Corey lactone. δ-Tocotrienol
is widely reported to effectively suppress HMG-CoA
reductase activity and concomitantly lower serum total
cholesterol and LDL-cholesterol levels [30-34,40-43,69,70].
Quercetin suppresses HMG-CoA reductase activity
in vitro [71] and in vivo [72], and dietary intake of querce-
tin has been inversely correlated with total cholesterol and
LDL-cholesterol levels in Japanese women [73]. Choles-
terol levels in an elderly population were inversely corre-
lated with serum riboflavin levels [74]. Thus, our findings
that quercetin, and more potently, riboflavin lowered
serum cholesterol levels are supported by the literature
[72-74]. We also found that diet supplementation with
amiloride, an FDA approved diuretic, was least effective in
reducing total cholesterol level (9%). This finding is some-
what similar to results of a human study which showed
that serum total cholesterol levels were not altered in sub-
jects receiving amiloride concomitantly with hydrochlor-
othiazide [75]. Amiloride also failed to impact serum levels
of cardioprotective HDL-cholesterol in the current study.
HDL-cholesterol levels in chickens receiving quercetin,
riboflavin or (-) Corey lactone were modestly reduced.
Combining δ-tocotrienol with these compounds failed to
raise HDL-cholesterol. On the other hand, the anti-inflam-
matory compound, dexamethasone, dramatically increased
serum HDL-cholesterol level.
All compounds other than dexamethasone resulted
in a significant lowering of serum triglyceride levels
Table 6 Microarray analyses of RNA of livers of chickens after treatment with various compounds
Genes up-regulated by the first four lipid-lowering compounds,
and down-regulated by dexamethasone
# Genes Control δ-T3 Quer Ribo Co lac Dexa Description
1 CR353609 4.47 7.23 7.13 6.67 7.12 3.95 Finished cDNA, clone CHEST110e20
2 AJ720605 3.07 5.39 5.65 5.23 5.04 2.66 Ornithine aminotransferase
3 BX265212 2.81 4.72 5.12 4.54 5.14 2.38 Similar to L-Kynurenine hydrrlase
4 CR405837 2.76 4.89 5.27 4.49 4.95 1.89 Finished cDNA, clone CHEST884a21
5 BU250153 3.57 5.25 5.97 5.13 5.77 3.27 Selenoprotein P, plasma, 1
6 AJ720030 3.29 5.00 5.62 5.35 5.13 1.62 Squalene epoxidase
7 ENSGALT10 2.97 4.76 5.19 4.00 4.83 3.86 Assembly = WASHUC1|chr = 20|strand = forward|cdna
8 L07842 2.48 3.90 4.80 3.18 5.70 1.48 Antithrombin III
Genes Genes down-regulated by the first four lipid-lowering compounds,
and up-regulated by dexamethasone
1 CR389189 4.60 2.35 3.26 1.90 3.68 8.02 Finshed cDNA, clone CHEST613j 16
2 NM204114 3.82 0.66 2.35 1.33 2.22 5.97 Deiodenase, iodothyronine, type II
3 NM_205155 4.73 5.52 6.87 5.48 5.79 9.09 Fatty acid synthase
Genes Genes up-regulated only by dexamethasone
1 BU359098 0.84 1.08 1.04 1.25 0.88 3.69 BUB 1 uninhibited by benzimidazoles 1 homolog
Genes Genes down-regulated only by dexamethasone
1 BU384885 2.11 3.48 4.56 2.90 3.43 1.23 Hypothetical LOC771662
δ-T3 = δ-Tocotrienol; Quer. = Quercetin; Ribo = Riboflavin; Co lac = (-) Corey lactone; Dexa = Dexamethasone.
Qureshi et al. Lipids in Health and Disease 2011, 10:39
http://www.lipidworld.com/content/10/1/39
Page 18 of 22(Figure 8). The additive effect of combining δ-tocotrienol
with another compound, with the exception of amiloride,
on serum triglyceride was insignificant (Figure 8).
A recent report points to the superiority of the HDL-
cholesterol/total cholesterol (HDL-chol/TC) ratio for
monitoring cardiovascular risk compared to serum total
cholesterol and LDL-cholesterol levels [76]. With the
exceptions of those incorporating dexamethasone, all
treatments resulted in higher HDL-chol/TC ratios than
that calculated for the control group (0.51). Within the
individual treatment group δ-tocotrienol (0.65; 127%),
riboflavin (0.61, 120%), (-) Corey lactone (0.68, 133%)
appear to be most effective in improving the ratios. The
ratio calculated for δ-tocotrienol + quercetin (0.65,
127%) was modestly improved relative to that calculated
for the quercetin group (0.56, 110%). These modest
improvements were also observed by δ-tocotrienol com-
bination with riboflavin (129%), and (-) Corey lactone
(145%), without improving amiloride or dexamethasone
ratios. In addition to the potential ability of quercetin,
to reduce the cumulative serum risk factors for cardio-
vascular disease (total cholesterol, LDL-cholesterol, tri-
glyceride, NO and TNF-a levels) we found exceptional
risk-reducing value in two vitamins, δ-tocotrienol
(a member of the vitamin E group; Figure 1), and ribo-
flavin when fed at levels 4- and 10-times higher, respec-
tively, than those normally found in commercial chicken
feed. Based on the data presented in this study, it is rea-
sonable to propose that supplementing a 2500 kcal diet
with 40 mg of either vitamin (i.e. δ-tocotrienol or ribo-
flavin) could be potentially beneficial in reducing cardio-
vascular disease risk in humans.
Microarray analyses of liver samples identified 62
genes whose expression was up-regulated (39 genes) or
down-regulated (23 genes) by all compounds suggesting
common impact on serum levels of TNF-a,N O ,a n d
lipid parameters. The most important up-regulated gene
expression modulated by these compounds were asso-
ciated with cytokine signaling, NFBa n du b i q u i t i np r o -
tein lipase (inflammation), heat shock protein, RIKEN
cDNA, T cell receptor gamma (ageing), FAS, myosin,
squalene epoxidase, NADH dehydrogenase, Prostaglan-
din D (cardiovascular disease), and RAN, member RAS
oncogene family (cancer). The down-regulated genes
were associated with proteasome, tumor necrosis factor
(inflammation), carnitine palmitoyltransferase1A (age-
ing), glycogen synthase kinase, glutathione S-transferase
(cardiovascular disease), and Jun oncogene (cancer) as
reported earlier [76-80]. The microarray array analyses
further identified several other genes whose expression
was differentially impacted by the compounds shown to
lower serum lipid levels and dexamethasone, associated
with markedly elevated serum lipids.
Conclusions
Levels of serum markers for risk of inflammatory dis-
eases (NO and TNF-a) are decreased by oral dietary
treatments supplemented with naturally-occurring, syn-
thetic or FDA approved compounds, δ-tocotrienol, quer-
cetin, riboflavin, dexamethasone, (-) Corey lactone, and
a diuretic, amiloride. When administered in combination
with an apparently saturating dose of δ-tocotrienol, the
risk-lowering impact of the remaining compounds was
only modestly increased. Therefore, this finding suggests
the possibility of a pronounced additive effect in the
presence of a lower dose of the δ-tocotrienol. Serum
NO levels increase during ageing process, as a conse-
quence of a diminished regulation of the activation of
NF-B signaling [1,2]. These compounds may also block
the activation of NF-B and result in lowering serum
TNF-a and NO levels. Confirming numerous reports, δ-
tocotrienol, a post-transcriptional suppressor of HMG-
CoA reductase activity, effectively lowered serum total
cholesterol, LDL-cholesterol and triglyceride levels.
Moreover, treatments incorporating the anti-inflamma-
tory compounds, quercetin, riboflavin, and (-) Corey lac-
tone alone and in combination with δ-tocotrienol
resulted in lower serum total and LDL-cholesterol levels.
However, anti-inflammatory dexamethasone increased
serum lipid levels, actions partially attenuated in the
presence of δ-tocotrienol. These novel findings demon-
strate the potential value to be gained through investiga-
tions of the impact of various nutritional supplements,
specifically the flavonoids, alone and in combination
with δ-tocotrienol on predictors of age-associated
diseases.
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